Intellipharmaceutics International Inc. (IPCI)

[Tekterra]

Speaking of competitions, Rexista will be competing with Collegium Xtampza, and Pfizer Troxyca ER, and of course Purdue Oxycontin ER reformulated version.

The only advantage Rexista had was the stigma tizing dye. It flags early sign of abuse.

With Collegium and Pfizer both in the market now they should take a good chunk of the market share in the coming year. With 4 players the potential is 25% assuming equally distributed. But, we know that won't be the case so it's hard to say how things will turn out for Rexista.

EGLT ARYMO targets the morphine market that doesn't directly compete with IPCI but it's still in the same pain management market.